Skip to content

A parallel controlled clinical study of mesenchymal stem cells in the treatment of X-linked hypophosphemic rickets (XLHR)

A parallel controlled clinical study of mesenchymal stem cells in the treatment of X-linked hypophosphemic rickets (XLHR)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047599
Enrollment
Unknown
Registered
2021-06-20
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

X-linked hypophosphoric rickets

Interventions

Sponsors

Shandong Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 1-12 years; 2. A definite diagnosis of X-linked hypophosphatemic rickets (PHEX gene mutation) through pathogenic gene testing; 3. Rickets severity score of at least 2 points; 4. Fasting serum phosphorus lower than 0.97 mmol/L (3 mg/dL).

Exclusion criteria

Exclusion criteria: 1. The height is 50% higher than the average height of children of the same age and sex; 2. The application of growth hormone within 1 year before the test screening; 3. Brain disease, abnormal judgment ability; mental illness unable to cooperate; 4. Those who have participated in other clinical trials within the first three months of this trial; 5. Malignant tumor, active tuberculosis or taking glucocorticoid drugs; 6. Combined with other diseases, and the researchers believe that it affects the evaluation of efficacy or poor compliance; 7. White blood cell count <3.0x10^9/L, or platelets <100x10^9/L, or hemoglobin <90g/L; 8. For any other reason, the investigator considers it inappropriate to participate in the trial; 9. Those who are allergic to all the drugs in this test or their ingredients, or have allergies to the current symptoms, or those who have hypersensitivity constitution.

Design outcomes

Primary

MeasureTime frame
Imaging global impression change score;Thacher rickets severity score;

Secondary

MeasureTime frame
Height;Maximum tubular phosphorus reabsorption rate;Fractional urinary phosphate excretion;

Countries

China

Contacts

Public ContactZhao Jiajun
jjzhao@sdu.edu.cn+86 13708932909

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026